Holen Sie sich die Stockscreener-App
91.38
3.18%
2.82
Vorhandelsmarkt:
91.38
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Comet
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Press & Sun-Bulletin
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Livingston Daily
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Daytona Beach News-Journal
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - STT Info
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Central New Jersey News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Insider Monkey
What dividend safety score for Protagonist Therapeutics Inc. stock2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
How currency fluctuations impact Protagonist Therapeutics Inc. stock2025 Year in Review & Scalable Portfolio Growth Ideas - Newser
How Protagonist Therapeutics Inc. stock compares to growth peers2025 Earnings Surprises & High Accuracy Investment Entry Signals - Newser
Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Nasdaq Futures Therapeutic Edge - Kalkine Media
Skandinaviska Enskilda Banken AB publ Lowers Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Trading Systems Reacting to (PTGX) Volatility - news.stocktradersdaily.com
Ensign Peak Advisors Inc Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Creative Planning - MarketBeat
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Oak Ridger
Why Protagonist Therapeutics Inc. stock remains undervaluedDividend Hike & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Newswire.com
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq
Jefferies Financial Group Inc. Buys 192,126 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
J.P. Morgan Keeps Their Buy Rating on Protagonist Therapeutics (PTGX) - The Globe and Mail
Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada
What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Officer Molina Surrenders 2,712 Of Protagonist Therapeutics Inc [PTGX] - TradingView
Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com
What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com
Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):